Clinical Trials

Multiple Myeloma, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Active not recruiting

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

119 enrolled

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT07069595 2026-03-05

PREDICT-RD

78 enrolled

Phase NA Not yet recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07291921 2026-03-03

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Recruiting

100 enrolled

Thoracic

Lung Neoplasms, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

330 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

70 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Colonic Neoplasms, Neoplasm, Residual

NCT05987696 2026-02-11

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase 1 Completed

2 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07392970 2026-02-06

Motixafortide for MRD Sensitization in AML

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05429320 2026-02-02

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Not yet recruiting

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

40 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Phase 2 Completed

42 enrolled 11 charts

Phase NA Not yet recruiting

Multiple Myeloma, Neoplasm, Residual

NCT07356882 2026-01-21

EURHOLY

Recruiting

400 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

276 enrolled

Recurrence, Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

42 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT05625971 2026-01-07

NIRVANA

Completed

36 enrolled

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Phase NA Active not recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06744075 2025-12-30

CELERITY

108 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

190 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

23 enrolled

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04679285 2025-12-23

FERTILAM

Completed

9 enrolled